Cannabinoids inhibit the synaptic uptake of adenosine and dopamine in the rat and mouse striatum

European Journal of Pharmacology

Volumn 655, Issue 1-3, 2011, Pages 38-45

  Pandolfo, Pablo ^a,b   Silveirinha, Vasco ^b   Santos Rodrigues, Alexandre Dos ^b,c   Venance, Laurent ^d   Ledent, Catherine ^e   Takahashi, Reinaldo N ^a   Cunha, Rodrigo A ^b   Köfalvi, Attila ^b  

^a FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c FLUMINENSE FEDERAL UNIVERSITY   (Brazil)

^d Paris Sciences et Lettres   (France)

^e UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

Adenosine uptake; Cannabinoid; Dopamine uptake; Striatum; Synaptosome

Indexed keywords

1 [2 (BENZHYDRYLOXY)ETHYL] 4 (3 PHENYLALLYL)PIPERAZINE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 [6 METHOXY 2 (4 METHOXYPHENYL) 3 BENZOFURANYLCARBONYL]BENZONITRILE; ADENOSINE; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; DOPAMINE; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 55; GLUTAMIC ACID; PROTEIN INHIBITOR; THREO B BENZOLOXYASPARTICV ACID; UNCLASSIFIED DRUG; VANILLOID RECEPTOR 1;

ADENOSINE TRANSPORT; ANIMAL TISSUE; ARTICLE; BRAIN REGION; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE UPTAKE; DRUG RECEPTOR BINDING; LIGAND BINDING; MALE; MOUSE; NERVE ENDING; NONHUMAN; NUCLEIC ACID TRANSPORT; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; RAT; SYNAPTIC INHIBITION;

EID: 79952535110     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2011.01.013     Document Type: Article

References (54)

1. 1 cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo Biochem. J. 3 2000 817 824
2. 1 receptor-mediated modulation of dopamine release in different striatal compartments J. Neurochem. 101 2007 355 363 (Pubitemid 46525280)
3. M.G. Bossong, B.N. van Berckel, R. Boellaard, L. Zuurman, R.C. Schuit, A.D. Windhorst, J.M. van Gerven, N.F. Ramsey, A.A. Lammertsma, and R.S. Kahn Delta 9-tetrahydrocannabinol induces dopamine release in the human striatum Neuropsychopharmacology 34 2009 759 766
4. J.M. Brotchie Nondopaminergic mechanisms in levodopa-induced dyskinesia Mov. Disord. 20 2005 919 931 (Pubitemid 41419505)
5. N. Cabello, J. Gandía, D.C. Bertarelli, M. Watanabe, C. Lluís, R. Franco, S. Ferré, R. Luján, and F. Ciruela Metabotropic glutamate type 5, dopamine D2 and adenosine A2a receptors form higher-order oligomers in living cells J. Neurochem. 109 2009 1497 1507
6. E.J. Carrier, J.A. Auchampach, and C.J. Hillard Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression Proc. Natl. Acad. Sci. U. S. A. 103 2006 7895 7900
7. J.P. Chen, W. Paredes, J. Li, D. Smith, J. Lowinson, and E.L. Gardner Delta 9-tetrahydrocannabinol produces naloxone-blockable enhancement of presynaptic basal dopamine efflux in nucleus accumbens of conscious, freely-moving rats as measured by intracerebral microdialysis Psychopharmacology 102 1990 156 162 (Pubitemid 20264653)
8. N. Chen, M. Appell, J.L. Berfield, and M.E. Reith Inhibition by arachidonic acid and other fatty acids of dopamine uptake at the human dopamine transporter Eur. J. Pharmacol. 478 2003 89 95 (Pubitemid 37315726)
9. C.J. Chu, S.M. Huang, L. De Petrocellis, T. Bisogno, S.A. Ewing, J.D. Miller, R.E. Zipkin, N. Daddario, G. Appendino, V. Di Marzo, and J.M. Walker N-oleoyldopamine, a novel endogenous capsaicin-like lipid that produces hyperalgesia J. Biol. Chem. 278 2003 13633 13639 (Pubitemid 36799898)
10. 2A receptor heteromers J. Neurosci. 26 2006 2080 2087
11. 2A receptor-mediated facilitation of plasticity Neurochem. Int. 52 2008 65 72 (Pubitemid 350235700)
12. 2A receptors in psychiatric disorders Curr. Pharm. Des. 14 2008 1512 1524 (Pubitemid 351997816)
13. W.A. Devane, L. Hanus, A. Breuer, R.G. Pertwee, L.A. Stevenson, G. Griffin, D. Gibson, A. Mandelbaum, A. Etinger, and R. Mechoulam Isolation and structure of a brain constituent that binds to the cannabinoid receptor Science 258 1992 1946 1949 (Pubitemid 23026736)
14. L. Fattore, P. Fadda, M.S. Spano, M. Pistis, and W. Fratta Neurobiological mechanisms of cannabinoid addiction Mol. Cell. Endocrinol. 286 2008 97 107
15. 1 receptor to stimulation of cAMP accumulation J. Pharmacol. Exp. Ther. 84 1998 291 297 (Pubitemid 28109558)
16. S. Ferré, F. Ciruela, C. Quiroz, R. Luján, P. Popoli, R.A. Cunha, L.F. Agnati, K. Fuxe, A.S. Woods, C. Lluis, and R. Franco Adenosine receptor heteromers and their integrative role in striatal function Sci. World J. 7 S2 2007 74 85 (Pubitemid 350277595)
17. S. Ferré, S.R. Goldberg, C. Lluis, and R. Franco Looking for the role of cannabinoid receptor heteromers in striatal function Neuropharmacology 56 2009 226 234
18. S.G. Ferreira, T. Lomaglio, A. Avelino, F. Cruz, C.R. Oliveira, R.A. Cunha, and A. Köfalvi N-acyldopamines control striatal input terminals via novel ligand-gated cation channels Neuropharmacology 56 2009 676 683
19. E. Fino, J. Glowinski, and L. Venance Bidirectional activity-dependent plasticity at corticostriatal synapses J. Neurosci. 25 2005 11279 11287 (Pubitemid 43083702)
20. E. Fino, J.M. Deniau, and L. Venance Brief subthreshold events can act as Hebbian signals for long-term plasticity PLoS ONE 4 2009 e6557
21. G.L. Gerdeman, and J. Fernández-Ruiz The endocannabinoid system in the physiology and pathology of the basal ganglia A. Köfalvi, Cannabinoids and the Brain 2008 Springer US 423 484 10.1007/978-0-387-74349-3-21
22. A. Giuffrida, L.H. Parsons, T.M. Kerr, F. Rodríguez de Fonseca, M. Navarro, and D. Piomelli Dopamine activation of endogenous cannabinoid signaling in dorsal striatum Nat. Neurosci. 2 1999 358 363 (Pubitemid 30491279)
23. Gowran, A., Noonan, J., Campbell, V.A., in press. The multiplicity of action of cannabinoids; implications for treating neurodegeneration. CNS Neurosci. Ther. doi:10.1111/j.1755-5949.2010.00195.x.
24. 1 cannabinoid receptors Proc. Natl. Acad. Sci. U. S. A. 104 2007 20588 20593
25. S.M. Huang, T. Bisogno, M. Trevisani, A. Al-Hayani, L. De Petrocellis, F. Fezza, M. Tognetto, T.J. Petros, J.F. Krey, C.J. Chu, J.D. Miller, S.N. Davies, P. Geppetti, J.M. Walker, and V. Di Marzo An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors Proc. Natl. Acad. Sci. U. S. A. 99 2002 8400 8405 (Pubitemid 34651064)
26. A. Köfalvi Alternative interacting sites and novel receptors for cannabinoid ligands A. Köfalvi, Cannabinoids and the Brain 2008 Springer US 131 160 10.1007/978-0-387-74349-3-9
27. A. Köfalvi, and M. Fritzsche The endocannabinoid system is a major player in schizophrenia A. Köfalvi, Cannabinoids and the Brain 2008 Springer US 485 528 10.1007/978-0-387-74349-3-22
28. A. Köfalvi, R.J. Rodrigues, C. Ledent, K. Mackie, E.S. Vizi, R.A. Cunha, and B. Sperlágh Involvement of cannabinoid receptors in the regulation of neurotransmitter release in the rodent striatum: a combined immunochemical and pharmacological analysis J. Neurosci. 25 2005 2874 2884 (Pubitemid 40389245)
29. A.C. Kreitzer, and R.C. Malenka Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson′s disease models Nature 445 2007 643 647 (Pubitemid 46232883)
30. A.C. Kreitzer, and R.C. Malenka Striatal plasticity and basal ganglia circuit function Neuron 60 2008 543 554
31. S.R. Laviolette, and A.A. Grace The roles of cannabinoid and dopamine receptor systems in neural emotional learning circuits: implications for schizophrenia and addiction Cell. Mol. Life Sci. 63 2006 1597 1613 (Pubitemid 44252174)
32. 1 receptor knockout mice Science 283 1999 401 404
33. 2A antagonists J. Neurosci. 30 2010 2160 2164
34. 2A adenosine receptor Invest. Ophthalmol. Vis. Sci. 49 2008 5526 5531
35. D.T. Malone, and D.A. Taylor Modulation by fluoxetine of striatal dopamine release following Delta9-tetrahydrocannabinol: a microdialysis study in conscious rats Br. J. Pharmacol. 128 1999 21 26 (Pubitemid 29425263)
36. Y. Mizuno, K. Hasegawa, T. Kondo, S. Kuno, and M. Yamamoto Japanese Istradefylline Study Group. Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease: a randomized, controlled study Mov. Disord. 25 2010 1437 1443
37. 2A receptors and Parkinson's disease Handb. Exp. Pharmacol. 193 2009 589 615
38. H.A. Navarro, J.L. Howard, G.T. Pollard, and F.I. Carroll Positive allosteric modulation of the human cannabinoid (CB) receptor by RTI-371, a selective inhibitor of the dopamine transporter Br. J. Pharmacol. 156 2009 1178 1184
39. J.M. Ng Cheong Ton, G.A. Gerhardt, M. Friedemann, A.M. Etgen, G.M. Rose, N.S. Sharpless, and E.L. Gardner The effects of delta 9-tetrahydrocannabinol on potassium-evoked release of dopamine in the rat caudate nucleus: an in vivo electrochemical and in vivo microdialysis study Brain Res. 451 1988 59 68
40. P. Pandolfo, F.A. Pamplona, R.D. Prediger, and R.N. Takahashi Increased sensitivity of adolescent spontaneously hypertensive rats, an animal model of attention deficit hyperactivity disorder, to the locomotor stimulation induced by the cannabinoid receptor agonist WIN 55, 212-2 Eur. J. Pharmacol. 563 2007 141 148 (Pubitemid 46602239)
41. P. Pandolfo, L.F. Vendruscolo, R. Sordi, and R.N. Takahashi Cannabinoid-induced conditioned place preference in the spontaneously hypertensive rat-an animal model of attention deficit hyperactivity disorder Psychopharmacology 205 2009 319 326
42. R.G. Pertwee Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists Curr. Med. Chem. 17 2010 1360 1381
43. 1-independent inhibition of dopamine transporter activity by cannabinoids in mouse dorsal striatum J. Neurochem. 101 2007 389 396 (Pubitemid 46525277)
44. 2A receptors and basal ganglia physiology Prog. Neurobiol. 83 2007 277 292 (Pubitemid 350110609)
45. Y. Shigeri, K. Shimamoto, Y. Yasuda-Kamatani, R.P. Seal, N. Yumoto, T. Nakajima, and S.G. Amara Effects of threo-beta-hydroxyaspartate derivatives on excitatory amino acid transporters (EAAT4 and EAAT5) J. Neurochem. 79 2001 297 302 (Pubitemid 32988945)
46. K. Shimamoto, B. Lebrun, Y. Yasuda-Kamatani, M. Sakaitani, Y. Shigeri, N. Yumoto, and T. Nakajima DL-threo-beta-benzyloxyaspartate, a potent blocker of excitatory amino acid transporters Mol. Pharmacol. 53 1998 195 201 (Pubitemid 28099728)
47. M. Steffens, and T.J. Feuerstein Receptor-independent depression of DA and 5-HT uptake by cannabinoids in rat neocortex-involvement of Na+/K + -ATPase Neurochem. Int. 44 2004 529 538 (Pubitemid 38183303)
48. N. Stella, P. Schweitzer, and D. Piomelli A second endogenous cannabinoid that modulates long-term potentiation Nature 388 1997 773 778 (Pubitemid 27375156)
49. G. Tanda, F.E. Pontieri, and G. Di Chiara Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism Science 276 1997 2048 2050 (Pubitemid 27443611)
50. M. Uchigashima, M. Narushima, M. Fukaya, I. Katona, M. Kano, and M. Watanabe Subcellular arrangement of molecules for 2-arachidonoyl-glycerol- mediated retrograde signaling and its physiological contribution to synaptic modulation in the striatum J. Neurosci. 27 2007 3663 3676 (Pubitemid 46557660)
51. J.R. Wickens, J.C. Horvitz, R.M. Costa, and S. Killcross Dopaminergic mechanisms in actions and habits J. Neurosci. 27 2007 8181 8183 (Pubitemid 47219602)
52. 1 receptors in mood and anxiety disorders Behav. Pharmacol. 16 2005 315 331 (Pubitemid 41404804)
53. 2 receptor-mediated inhibition of glutamate release by retrograde endocannabinoid signaling Proc. Natl. Acad. Sci. U. S. A. 103 2006 8251 8256 (Pubitemid 43801084)
54. A.W. Zuardi, J.E. Hallak, S.M. Dursun, S.L. Morais, R.F. Sanches, R.E. Musty, and J.A. Crippa Cannabidiol monotherapy for treatment-resistant schizophrenia J. Psychopharmacol. 20 2006 683 686 (Pubitemid 44321696)